00:01 , May 11, 2019 |  BC Innovations  |  Translation in Brief

Arvinas, Palleon founders extend the reach of targeted degraders

A study from Arvinas founder Craig Crews is the second report in as many months of a technology geared to degrade extracellular proteins. The platforms open up new territory for targeted degradation therapies, on the...
23:51 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies suggest Tregs or factors secreted by Tregs could help treat MI. In primary rat cardiomyocytes, supernatant derived from the media of primary rat Treg cultures increased...
17:02 , Feb 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest IGF-2 could help treat autism. In a mouse model of autism, a single subcutaneous 30 μg/kg dose of IGF-2 decreased social interaction deficits, long-term non-aversive and aversive memory deficits and...
21:21 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

BioMarin reports Phase I/II data for BMN 250 in mucopolysaccharidosis IIIB

In September, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported interim data from 3 patients with mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo type B syndrome) in the dose-escalation portion of the Phase I/II BMN 250-201 trial showing that intracerebroventricular...
07:00 , Aug 1, 2016 |  BioCentury  |  Product Development

IGF synergy in cancer

Despite a history of failures in targeting the insulin-like growth factor receptor for cancer, Boehringer Ingelheim GmbH and Eli Lilly and Co. have several hypotheses that support greater cell cycle arrest and the potential to...
07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
07:00 , May 19, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Tumor-homing peptides CGKRK and RGF for targeting therapies to the placenta

Drug delivery TECHNOLOGY: Peptides Tumor-homing peptides could be used to target therapies to the placenta. In pregnant mice, the peptides CGKRK and RGF, which bind tumor antigens calreticulin (CALR) and integrin α5 ( CD49e ),...
07:00 , May 2, 2016 |  BC Week In Review  |  Clinical News

BMN 250: Phase I/II started

BioMarin began the open-label, dose-escalation, international Phase I/II BMN 250-201 trial to evaluate BMN 250 given via intracerebroventricular infusion. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif.   Product: BMN 250   Business: Endocrine/Metabolic   Molecular...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Reveglucosidase Alfa: Interim Phase II data

Interim data from 18 evaluable patients previously treated with Myozyme / Lumizyme alglucosidase alfa for >=48 weeks in the single-arm, open-label, international Phase II INSPIRE trial showed that 20 mg/kg IV reveglucosidase alfa every other...
07:00 , Mar 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: GATA binding protein 2 (GATA2); insulin-like growth factor-2 (IGF-2)

Cancer INDICATION: Prostate cancer In vitro and mouse studies suggest inhibiting GATA2- IGF2 signaling could resensitize prostate cancer to chemotherapy. In chemotherapy-resistant human prostate cancer cells, levels of the transcription factor GATA2 and its target...